Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Operating Income Loss of -$231.75 million for the year ending 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +15.2% in Operating Income Loss from 2024 to 2025.
- This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.71 million | Q2 2014: -$2.19 million | Q3 2014: -$2.09 million | Q1 2015: -$3.05 million | Q2 2015: -$3.68 million | Q3 2015: -$5.44 million | Q1 2016: -$10.14 million | Q2 2016: -$8.78 million | Q3 2016: -$10.72 million | Q1 2017: -$2.87 million | Q2 2017: -$3.52 million | Q3 2017: -$6.73 million | Q4 2017: -$6.66 million | Q1 2018: -$14.41 million | Q2 2018: -$14.87 million | Q3 2018: -$15.33 million | Q4 2018: -$26.55 million | Q1 2019: -$18.95 million | Q2 2019: -$18.39 million | Q3 2019: -$19.17 million | Q4 2019: -$19.65 million | Q1 2020: -$24.12 million | Q2 2020: -$23.56 million | Q3 2020: -$27.39 million | Q4 2020: -$59.24 million | Q1 2021: -$39.22 million | Q2 2021: -$34.05 million | Q3 2021: -$49.65 million | Q1 2022: -$42.56 million | Q2 2022: -$54.21 million | Q3 2022: -$58.49 million | Q1 2023: -$62.19 million | Q2 2023: -$68.76 million | Q3 2023: -$65.43 million | Q1 2024: -$67.38 million | Q2 2024: -$73.71 million | Q3 2024: -$69.42 million | Q1 2025: -$64.39 million | Q2 2025: -$71.15 million | Q3 2025: -$52.25 million.
- Over the full 12 years of available data (2014 to 2025), ROCKET PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 2,908.1%.
- Historical annual values: Fiscal year 2025: -$231.75 million | Fiscal year 2024: -$273.21 million | Fiscal year 2023: -$259.66 million | Fiscal year 2022: -$224.34 million | Fiscal year 2021: -$167.25 million | Fiscal year 2020: -$134.30 million | Fiscal year 2019: -$76.15 million | Fiscal year 2018: -$71.16 million | Fiscal year 2017: -$19.77 million | Fiscal year 2016: -$7.57 million | Fiscal year 2015: -$20.40 million | Fiscal year 2014: -$7.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: